Studieoverzicht

 
 
  2022-05 EMBER-4       Open       Adjuvant       HER2- HR+       Both pre- and postmenopausal  
  2021-01 SEQUEL-Breast       Open       Advanced/metastatic       HER2- HR+       Both pre- and postmenopausal